ASMB vs. OMER, NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTS
Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Omeros (OMER), Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.
Assembly Biosciences vs. Its Competitors
Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
48.8% of Omeros shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 12.3% of Omeros shares are owned by insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Omeros received 508 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.61% of users gave Omeros an outperform vote while only 58.65% of users gave Assembly Biosciences an outperform vote.
Omeros presently has a consensus price target of $18.00, indicating a potential upside of 397.24%. Assembly Biosciences has a consensus price target of $33.00, indicating a potential upside of 93.55%. Given Omeros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Omeros is more favorable than Assembly Biosciences.
Assembly Biosciences has higher revenue and earnings than Omeros. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
In the previous week, Omeros had 10 more articles in the media than Assembly Biosciences. MarketBeat recorded 18 mentions for Omeros and 8 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.86 beat Assembly Biosciences' score of 0.16 indicating that Omeros is being referred to more favorably in the media.
Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -144.05%. Omeros' return on equity of 0.00% beat Assembly Biosciences' return on equity.
Omeros has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
Summary
Omeros beats Assembly Biosciences on 15 of the 18 factors compared between the two stocks.
Get Assembly Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assembly Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ASMB) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ASMB Stock Free ASMB Stock Alerts